Amylyx Pharmaceuticals, Inc. (AMLX) News
Track canonical SquawkNews coverage tagged to AMLX, Amylyx Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, Septe
NEWS | Sep 23, 2026, 01:00 PM UTC
L
Amylyx Pharmaceuticals Insiders Sold Shares Worth Over $1.9M
Justin B. Klee, a director and Co-Chief Executive Officer, sold common stock in automatic transactions to cover tax withholding on vested performance stock units at weighted average sale prices of $32.1293 for one block
EQUITY | Sep 14, 2026, 08:01 PM UTC
M
Amylyx signs avexitide supply deals with Bachem and Polypeptide
Amylyx Pharmaceuticals entered two non-exclusive agreements for long-term avexitide commercial supply. It signed a five-year Manufacturing and Supply Agreement with Bachem starting in 2028 and a separate agreement with P
EQUITY | Sep 08, 2026, 09:03 PM UTC
L
Amylyx Pharmaceuticals maintained at Buy by Guggenheim
Guggenheim maintained its Buy rating on Amylyx Pharmaceuticals.
EQUITY | Aug 27, 2026, 01:55 PM UTC
M
AMLX, EDSA, QNBC price secondary share offerings
AMLX, EDSA and QNBC are among the names in a set of deals priced today, with AMLX pricing 14.1M shares at $35.50, EDSA 3.87M shares at $5.50 and QNBC 1.07M shares at $43.00.
MNA | Aug 20, 2026, 12:28 PM UTC
M
ANDG and AMLX secondary deals set to price today
ANDG will price a 4.28M share secondary offering today with price TBD, while AMLX has a $350M secondary deal announced last night with shares and pricing TBD.
MNA | Aug 19, 2026, 12:54 PM UTC
L
Guggenheim raises AMLX price target to $55, keeps Buy
Guggenheim raises its AMLX price target from $40 to $55 and maintains a Buy rating, with no catalyst supplied in the alert.
EQUITY | Aug 19, 2026, 12:32 PM UTC
H
Amylyx Pharmaceuticals proposes $350.0M common stock offering
Amylyx Pharmaceuticals (AMLX) announces a proposed $350.0M public offering of common stock, with proceeds to fund avexitide pre-commercial activities, R&D, and general corporate purposes.
EQUITY | Aug 18, 2026, 08:01 PM UTC
H
AMLX jumps on Phase 3 LUCIDITY avexitide topline results
ALXN-backed ally?—No: AMLX is up about 29% after positive topline results from the Phase 3 LUCIDITY clinical trial of avexitide, while HAE and BBWI also post gains and HD adds a 2% earnings move.
EARNINGS | Aug 18, 2026, 12:20 PM UTC
L
Mizuho raises Amylyx target to $30, keeps Outperform
Mizuho analyst Graig Suvannavejh raised Amylyx's price target to $30 from $24 and kept an Outperform rating after the Q2 report, citing updated launch pricing assumptions for avexitide.
EQUITY | Aug 17, 2026, 12:36 PM UTC
M
AMLX: Guggenheim Raises Target
Guggenheim analyst Seamus Fernandez maintains Buy on Amylyx Pharmaceuticals and raises the price target to $40
EQUITY | Jun 25, 2026, 02:12 PM UTC
M
AMLX Presents ALS Trial Data
Amylyx Pharmaceuticals presents data from first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 in ALS at ENCALS 2026
EQUITY | Jun 23, 2026, 11:00 AM UTC